(CVM) CEL-SCI Corporation Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CVM) CEL-SCI Corporation Complete Analysis Pack
CEL-SCI Business Model Canvas: Biotech Strategy at a Glance
Unlock the full strategic blueprint behind CEL-SCI Corporation’s business model. This concise Business Model Canvas breaks down how the company creates value, manages key partnerships, and positions itself in a high-stakes biotech market. Ideal for investors, analysts, and strategists looking for clear, actionable insight. Download the full version to go deeper.
Partnerships
University of Georgia Center for Vaccines and Immunology
CEL-SCI Corporation’s partnership with the University of Georgia Center for Vaccines and Immunology supports preclinical and translational work on the LEAPS COVID-19 immunotherapy platform. By tapping the center’s vaccine and immunology expertise, CEL-SCI broadens its research reach beyond its own lab base and strengthens the LEAPS pipeline for future development.
Phase III clinical trial sites
CEL-SCI Corporation’s Multikine Phase III program for head and neck cancer depends on trial sites to enroll the planned 928 patients, deliver dosing, and collect survival and response data. These sites are the core of late-stage execution, and the company’s ability to run them well drives the quality and speed of the readout.
Contract research organizations
In fiscal 2025, CEL-SCI Corporation still needed contract research organizations to run complex clinical work, since CROs handle data management, site monitoring, and multi-country trial logistics that small biotech teams can’t absorb alone. This cuts internal load during large programs like Multikine and helps CEL-SCI keep trial execution moving without building a full in-house operations stack.
Clinical biologics manufacturers
CEL-SCI relies on clinical biologics manufacturers to make investigational supply for Multikine, since process control and batch consistency are critical in Phase 3 and preclinical work. These partners help keep clinical material available on time, which matters when a late-stage trial can need repeated, GMP-grade lots across multiple sites.
- External GMP supply for investigational biologics
- Supports batch consistency and process control
- Helps late-stage and preclinical production
Academic and research institutions
CEL-SCI Corporation’s LEAPS platform depends on academic and research partners for discovery work and mechanism studies; this matters because the Company reported $0 revenue in FY2025, so external science helps stretch its cash into new data. These ties can also support work beyond oncology, including broader immune-mediated uses.
- Universities help validate LEAPS biology.
- Research centers de-risk new indications.
- FY2025 revenue was $0.
CEL-SCI’s Partnerships Power Multikine and LEAPS in FY2025
CEL-SCI Corporation’s key partnerships center on universities, clinical trial sites, CROs, and GMP biologics makers. In FY2025, these links supported a $0-revenue company by supplying research expertise, patient enrollment, trial operations, and investigational material for Multikine and LEAPS.
| Partner | Role | FY2025 data |
|---|---|---|
| University of Georgia | LEAPS research support | Preclinical collaboration |
| Trial sites | Multikine enrollment and data | 928 patients planned |
| CROs and GMP makers | Trial ops and supply | Needed for Phase 3 |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for CEL-SCI Corporation, mapping its cancer immunotherapy strategy, partners, revenue path, and key operational priorities.
Customizable Excel Spreadsheet
Quickly spot CEL-SCI’s key business model pain points in one editable, board-ready snapshot.
Reference Sources
Provides a clear source trail for CEL-SCI Corporation, strengthening credibility and speeding investor decision-making.
Activities
Phase III Multikine development
CEL-SCI Corporation’s core activity is advancing Multikine through its Phase III trial in newly diagnosed, resectable locally advanced head and neck cancer. The program centers on trial design, global execution, and analysis across a planned 928-patient study, making this the company’s main value driver.
LEAPS platform research
CEL-SCI Corporation's LEAPS platform research develops Ligand Epitope Antigen Presentation System technology to modulate T-cell responses, with use cases explored in infectious disease, autoimmune, allergy, transplant, and cancer settings. In fiscal 2025, CEL-SCI remained a clinical-stage company with no product revenue, so LEAPS research stayed a core R&D spend driver.
Preclinical candidate advancement
CEL-SCI’s key activity is advancing four early-stage programs: LEAPS-H1N1-DC, LEAPS COV-19, CEL-2000, and CEL-4000. They are still in research or preclinical development, so the company is building future pipeline depth beyond Multikine.
Clinical and regulatory operations
CEL-SCI Corporation’s clinical and regulatory operations keep its Phase 3 Multikine program aligned with FDA and other authority rules, with quality control built into every trial step. This matters because late-stage immunotherapy work lives or dies on protocol compliance, data integrity, and inspection readiness, all of which support trial continuity and the path to approval.
- Coordinates with regulators
- Maintains clinical quality standards
- Protects trial continuity
Patent and IP management
CEL-SCI’s patent and IP management protects its LEAPS technology, which is central to keeping its biotech platform exclusive and defendable. In biotech, IP is the asset that can turn R&D spend into future licensing value, and CEL-SCI’s patent estate is a key part of that strategy.
- Protects LEAPS technology exclusivity
- Supports future licensing deals
- Strengthens long-term IP value
CEL-SCI’s 2025 Focus: Multikine Trial Execution and LEAPS R&D
CEL-SCI Corporation’s key activities are running the Phase III Multikine trial, keeping FDA-grade clinical and regulatory operations tight, and advancing LEAPS platform research. In fiscal 2025, CEL-SCI remained clinical-stage with no product revenue, so trial execution and R&D were the core spend areas.
| Metric | FY2025 |
|---|---|
| Product revenue | $0 |
| Main clinical program | Multikine Phase III |
| Pipeline focus | LEAPS R&D |
Preview Before You Purchase
Business Model Canvas
This preview shows the actual CEL-SCI Corporation Business Model Canvas you’ll receive after purchase—no mockup, no sample, and no hidden changes. The document is delivered in the same format, layout, and content structure you see here, so you know exactly what to expect. Once your order is complete, you’ll get instant access to this same ready-to-use file for editing, presenting, or sharing.
Resources
Multikine asset
Multikine is CEL-SCI Corporation's lead clinical asset and the main driver of its near-term value. It is in a 928-patient Phase III study for head and neck cancer, so progress on this program matters most for the Company Name's business model and financing outlook.
LEAPS patent portfolio
CEL-SCI's LEAPS patent portfolio protects its T-cell modulation platform, which is the core of its immune-oncology know-how. That IP ownership is central to competitive positioning because it supports exclusivity around the LEAPS approach and helps defend future licensing or development value.
Pipeline candidates
CEL-SCI Corporation’s key resources include four pipeline candidates: LEAPS-H1N1-DC, LEAPS COV-19, CEL-2000, and CEL-4000. They cover infectious disease and rheumatoid arthritis, giving the Company 4 shots at future development value across 2 therapeutic areas.
Scientific and clinical know-how
CEL-SCI Corporation’s key resource is its specialized immunology and clinical development know-how, which is critical for running a Phase III oncology program; its lead study has enrolled 928 patients. This expertise supports Multikine development and gives CEL-SCI the know-how to extend its platform into new cancer uses.
- Specialized immunology expertise
- Phase III trial execution
- 928-patient oncology study
- Supports platform expansion
Vienna Virginia headquarters
CEL-SCI Corporation, established in 1983, is headquartered in Vienna, Virginia, where it anchors corporate, research, and administrative work. The Vienna base is the company’s operating hub and supports day-to-day control of its vaccine development platform and public-company functions.
- Founded: 1983
- Headquarters: Vienna, Virginia
- Role: Corporate, research, administrative base
CEL-SCI’s Core Assets: Multikine, LEAPS IP, and Clinical Execution
CEL-SCI Corporation’s key resources are Multikine, its lead 928-patient Phase III asset for head and neck cancer, and its LEAPS patent portfolio, which protects the T-cell modulation platform. Its Vienna, Virginia base and immunology team support clinical execution and keep the Company Name’s pipeline moving.
| Resource | Key data |
|---|---|
| Multikine | Phase III, 928 patients |
| LEAPS IP | Platform protection |
| Headquarters | Vienna, Virginia |
Value Propositions
Phase III head and neck cancer immunotherapy
Multikine is CEL-SCI Corporation’s lead program and a Phase III immunotherapy for previously untreated locally advanced squamous cell carcinoma of the head and neck. Its 928-patient late-stage dataset makes it the company’s strongest clinical value proposition, with the biggest upside tied to a high-unmet-need cancer market.
Broad T-cell modulation platform
LEAPS is CEL-SCI Corporation’s T-cell modulation platform, built to steer immune responses instead of targeting just one disease. That platform model lets CEL-SCI Corporation adapt the same immune-engineering base across multiple indications, so the value proposition is broader than a single-product bet.
Multi-indication potential
CEL-SCI’s platform is built for multi-indication use across cancer, infectious disease, autoimmune disease, allergies, and transplantation, so one technology can serve several therapeutic markets. That breadth matters: the U.S. oncology drug market alone is already measured in the tens of billions of dollars, and a platform that can reach multiple diseases can spread R&D risk and raise long-term strategic value.
Non-antibiotic infection approach
CEL-SCI Corporation’s LEAPS-based programs aim to trigger the body’s own immune response against bacterial, viral, and parasitic infections, so they differ from direct antimicrobial drugs. This can fit alongside antibiotics, vaccines, and isolation protocols, especially as antimicrobial resistance stays a major global threat flagged by WHO.
- Immune activation, not pathogen killing
- Targets broad infection types
- Can complement infection control
Proprietary immunotherapy innovation
CEL-SCI Corporation’s value proposition is its proprietary immunotherapy platform, built around biologic and peptide-based therapy rather than chemistry-only drugs. That matters because its lead asset, Multikine, is designed to use the body’s immune system in first-line cancer care, and the company has reported no product revenue in recent filings, so the market story still rests on clinical differentiation.
- Immune-based, not small-molecule, therapy
- Proprietary biologic and peptide tech
- Value tied to clinical proof, not sales
CEL-SCI’s Multi-Platform Bet Hinges on Multikine Trial Proof
CEL-SCI Corporation’s value proposition is a proprietary immune-based platform led by Multikine, a 928-patient Phase III first-line head and neck cancer program aimed at a high-unmet-need market. LEAPS adds a second pillar: a peptide platform that can be applied across cancer and infectious, autoimmune, and transplant uses.
That mix gives CEL-SCI Corporation clinical differentiation and pipeline breadth, but its value still depends on trial proof because recent filings show no product revenue.
| Metric | Data |
|---|---|
| Multikine trial size | 928 patients |
| Product revenue | None reported |
| Platform reach | Multi-indication |
Customer Relationships
Clinical investigator collaboration
CEL-SCI works closely with clinical investigators in its Phase 3 Multikine program, and that tie is key to patient enrollment, protocol adherence, and clean data capture. Strong investigator support also helps keep trial sites aligned on follow-up, which can reduce missing data and improve study quality.
Academic research engagement
CEL-SCI Corporation uses university partners to move early-stage immunology work forward, share research goals, and build scientific validation for LEAPS. This model matters because LEAPS is still in development, so outside academic support can help de-risk the science before larger clinical spending.
Regulatory scientific interaction
CEL-SCI Corporation keeps active scientific talks with regulators, especially around its Phase 3 Multikine program, which enrolled 928 patients in head and neck cancer. These meetings help shape trial design, endpoints, and safety rules, and they are central to approval readiness as the company moves toward an FDA filing path.
Partner support and knowledge transfer
CEL-SCI’s partner support depends on sharing technical and scientific data fast, while keeping internal teams aligned with external experts. That matters in a Phase 3 setting like Multikine, which enrolled 928 patients, because moving a program from research into development needs tight handoffs and clear documentation.
With no product revenue in fiscal 2025, CEL-SCI must make knowledge transfer efficient so partners can help reduce delay and rework.
- Share trial data and methods quickly
- Align R&D, clinical, and partner teams
- Speed the move into development
Investor communications
CEL-SCI Corporation uses investor communications to keep shareholders and the market updated on Multikine trial progress, pipeline milestones, and financing needs. As a public biotech, this channel is key to capital access, especially while it funds late-stage clinical work and follows SEC reporting requirements.
- Trial updates shape market confidence.
- Financing news affects runway and dilution.
- Clear updates support future capital access.
CEL-SCI’s Key Lifeline: Trials, Regulators, and Investors
CEL-SCI Corporation’s customer relationships are mostly with clinical investigators, regulators, and investors, because its business still centers on advancing Multikine and LEAPS rather than selling products. In fiscal 2025, CEL-SCI reported no product revenue, a net loss of about $23.8 million, and cash of about $6.0 million, so these ties are critical for trial execution and funding access.
| Relationship | Why it matters | 2025 data |
|---|---|---|
| Investigators | Enrollment and data quality | Multikine Phase 3: 928 patients |
| Regulators | Trial design and approval path | Key for FDA filing readiness |
| Investors | Capital and runway | No product revenue; $23.8M net loss |
Channels
Clinical trial sites
Clinical trial sites are CEL-SCI Corporation’s main execution channel for Multikine, a Phase III head and neck cancer program. These oncology sites connect the Company with investigators and patients, and they handle screening, dosing, follow-up, and data capture.
This channel drives enrollment and trial quality, which matters because Phase III studies are the last step before a potential approval decision.
Academic partnership networks
Academic partnership networks give CEL-SCI Corporation access to specialized labs and research talent, which can speed up immunotherapy work and validate results. Its University of Georgia collaboration is a clear example of how academic ties support scientific advancement and help move research from lab studies toward clinical use.
Scientific conferences and publications
CEL-SCI Corporation uses scientific conferences and peer-reviewed publications to share clinical data with oncologists, researchers, and trial sites. This helps build trust around its Multikine program and keeps the platform visible in a field where credibility is often shaped by published evidence and conference exposure.
SEC filings and investor relations
CEL-SCI Corporation uses SEC filings and investor relations as its main public-company channel, with Form 10-K, Form 10-Q, 8-K, and investor updates sharing operating, liquidity, and financing details. This keeps market access open, supports transparency, and helps the Company communicate dilution, cash needs, and clinical progress clearly to investors.
- SEC filings disclose financials and risks
- Investor updates support funding efforts
- Public reporting builds market trust
Licensing and partnering outreach
CEL-SCI Corporation’s licensing and partnering outreach is the main route to turn Multikine, its one lead oncology asset, into revenue without heavy balance-sheet spend. Business development talks with pharma partners can shift future commercialization to out-licensing or co-development, which matters because one partnered deal can fund development and create non-dilutive value.
- One lead asset: Multikine.
- Out-licensing can reduce cash burn.
- Co-development can speed launch.
- Partner deals can add non-dilutive capital.
CEL-SCI’s Key Channels Power Multikine’s Phase III Progress
CEL-SCI Corporation’s key channels are clinical trial sites, academic partners, conferences, SEC reporting, and business-development outreach, all centered on Multikine. These channels move data, recruit investigators and patients, and keep investors and potential partners informed while the Phase III program advances.
| Channel | Use |
|---|---|
| Clinical sites | Phase III enrollment |
| SEC filings | Liquidity and risk disclosure |
| Partners | Out-licensing talks |
Customer Segments
Head and neck cancer patients
Head and neck cancer patients are CEL-SCI Corporation’s lead clinical customer segment for Multikine, with the Phase III program enrolling 928 patients across 23 countries. Their participation is the core driver of efficacy readouts, so trial outcomes directly shape Multikine’s path to approval and future commercial demand.
Oncology hospitals and treatment centers
Oncology hospitals and treatment centers run diagnosis, infusion, surgery, radiation, and trial enrollment, and the global cancer burden reached 20.0 million new cases and 9.7 million deaths in 2022, keeping these sites central to adoption. They are the main users of advanced immunotherapies and the trial hubs CEL-SCI relies on for study operations and real-world treatment delivery.
Pharma and biotech partners
CEL-SCI’s pharma and biotech partners are the main path to monetize its platform without funding every step itself. With 1 lead late-stage program and 0 approved products, partnerships can bring development cash, licensing fees, and milestone payments, while also helping with commercialization.
This segment matters most at the value-capture stage, when a partner can turn trial data into revenue faster than CEL-SCI alone. In biotech, deals often combine upfront cash, R&D support, and sales rights, so partner strength can directly shape the size and timing of returns.
Academic and research institutions
Academic and research institutions support CEL-SCI Corporation’s LEAPS work by running mechanism studies, assay validation, and preclinical testing. In FY2025, this matters because CEL-SCI is still a development-stage company, so universities and research centers help lower early R&D risk before larger clinical spend.
- Validate LEAPS immune mechanisms
- Advance preclinical proof-of-concept
- Cut early research cost and time
Public health and infectious disease programs
LEAPS COV-19 and LEAPS-H1N1-DC point CEL-SCI Corporation toward public health buyers that fund outbreak response, vaccine R&D, and stockpile programs; WHO still estimates seasonal influenza causes 290,000 to 650,000 respiratory deaths each year. This segment fits the platform’s immune-response focus, and adoption would likely come through government and global health partners.
- Targets outbreak and pandemic programs
- Fits influenza and COVID-19 use cases
- Public health agencies could be buyers
CEL-SCI’s Big Market: Cancer, Flu, and Global Trial Demand
CEL-SCI Corporation’s core customer segments are head and neck cancer patients, oncology hospitals, pharma partners, academic labs, and public-health buyers. The Phase III Multikine study enrolled 928 patients across 23 countries, while cancer cases hit 20.0 million in 2022 and flu still causes 290,000 to 650,000 respiratory deaths a year.
| Segment | Role |
|---|---|
| Patients | Multikine trial demand |
| Hospitals | Enroll and treat |
| Partners | Fund and commercialize |
Cost Structure
Clinical trial spending
Phase III development is CEL-SCI Corporation’s biggest cost driver, because patient enrollment, site monitoring, and data management make oncology studies expensive; late-stage cancer trials commonly cost $20M-$50M+ per program, and multicenter designs push spending higher.
Preclinical R and D
LEAPS candidates need lab work before they can be sold: assay testing, mechanism studies, and animal studies all sit in preclinical R and D. For CEL-SCI Corporation, this stage keeps cash tied up before revenue starts, since early science must be funded long before any commercialization.
Manufacturing and CMC
CEL-SCI Corporation’s Manufacturing and CMC spend is tied to producing Multikine under cGMP, where one failed batch can delay supply and add rework costs. With a Phase 3 program built around 928 patients, controlled lots, validation, testing, and release work are a core cost driver, but they also protect clinical supply and quality standards.
Regulatory and IP costs
CEL-SCI Corporation’s regulatory and IP spend is recurring and non-optional: U.S. patent maintenance fees hit at 3.5, 7.5, and 11.5 years after grant, and biotech trials must keep paying for FDA compliance, safety reporting, and CMC (chemistry, manufacturing, controls) work. For Multikine, those costs protect the platform but also keep cash burn high.
- Patent fees recur on fixed timelines.
- FDA compliance adds ongoing trial costs.
- IP defense protects CEL-SCI’s platform.
Corporate overhead
CEL-SCI Corporation’s corporate overhead is driven by public-company admin work: management, legal, finance, and investor relations, plus headquarters rent and support staff. For a small biotech, these costs are mostly fixed, so they pressure cash burn even when product revenue is limited.
- Management and board costs
- Legal and SEC reporting
- Finance and investor relations
- Headquarters fixed overhead
CEL-SCI’s Heavy Trial Costs Keep Cash Burn Elevated
CEL-SCI Corporation’s cost base is still dominated by Phase III oncology work, with multicenter trials often running $20M-$50M+ per program and 928 patients in Multikine’s study design. Preclinical LEAPS work, cGMP manufacturing, and FDA/CMC compliance keep spend high before revenue scales.
| Cost item | Key data |
|---|---|
| Phase III trial | 928 patients; $20M-$50M+ |
| Patent upkeep | 3.5, 7.5, 11.5 years post-grant |
| Overhead | Fixed public-company admin costs |
Revenue Streams
Equity financing
In fiscal 2025, CEL-SCI Corporation remained a clinical-stage biotech with no product revenue, so public equity access stayed its main cash source. Share issuances and other equity raises funded ongoing R and D, with research costs still driving most spending.
Research grants and contracts
CEL-SCI Corporation can use immunology and infectious disease grants and contracts to bring in non-dilutive cash before product approval, when trial costs are highest and revenue is still limited. These awards help pay for early-stage work, especially preclinical studies and Phase 1 to Phase 3 testing.
For a development-stage biotech like CEL-SCI Corporation, that funding can bridge the gap between discovery and commercialization and reduce pressure on equity dilution.
Collaboration and licensing fees
As of fiscal 2025, CEL-SCI Corporation reported no collaboration or licensing revenue, so any deal would add non-dilutive cash on top. Its LEAPS platform is the main partnerable asset and could bring upfront fees, milestones, or royalties.
Milestone payments
Milestone payments in CEL-SCI Corporation’s model would come from development partners and be tied to clear steps such as preclinical, clinical, or regulatory progress, so cash is earned as the program advances. In fiscal 2025, CEL-SCI reported no product revenue, which makes any future milestone cash more important as a non-dilutive funding source.
- Paid on preclinical or clinical progress
- Can follow FDA or other approvals
- Links cash to program advancement
Future product sales
CEL-SCI Corporation had no commercial product sales in FY2025, so future revenue from this stream still depends on regulatory approval. Multikine is the nearest-term candidate, and any LEAPS licensing deals could add future income if partnered programs reach the market.
- FY2025 product sales: $0
- Multikine is the lead near-term asset
- LEAPS could add licensed revenue
CEL-SCI Had No FY2025 Revenue, Relying on Equity Funding
In FY2025, CEL-SCI Corporation had no product, collaboration, or licensing revenue, so revenue streams were still limited to external funding and equity raises. That left Multikine and LEAPS as the main future cash drivers if approval or partnering occurs.
| Revenue stream | FY2025 data | Role |
|---|---|---|
| Product sales | $0 | None yet |
| Collaboration / licensing | $0 | Future upside |
| Equity funding | Primary cash source | Funds R&D |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.